WO2026061484A1 - Protéines de liaison à nkp80 et leurs utilisations - Google Patents

Protéines de liaison à nkp80 et leurs utilisations

Info

Publication number
WO2026061484A1
WO2026061484A1 PCT/CN2025/122554 CN2025122554W WO2026061484A1 WO 2026061484 A1 WO2026061484 A1 WO 2026061484A1 CN 2025122554 W CN2025122554 W CN 2025122554W WO 2026061484 A1 WO2026061484 A1 WO 2026061484A1
Authority
WO
WIPO (PCT)
Prior art keywords
nkp80
antigen
amino acid
seq
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/122554
Other languages
English (en)
Inventor
Mangge ZOU
Xin Huang
Yuncheng Zhao
Ying Gao
Yanmin CHEN
Wei Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Legend Biotech Ireland Ltd
Legend Biotech USA Inc
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Legend Biotech Ireland Ltd
Legend Biotech USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd, Legend Biotech Ireland Ltd, Legend Biotech USA Inc filed Critical Nanjing Legend Biotechnology Co Ltd
Publication of WO2026061484A1 publication Critical patent/WO2026061484A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une cellule immunitaire modifiée (par exemple, une cellule T modifiée) comprenant une protéine de liaison NKp80 (par exemple, un récepteur antigénique chimérique (CAR)) qui comprend un domaine de liaison NKp80 (par exemple, anti-NKp80 sdAb). L'invention concerne également des procédés de fabrication de ceux-ci et des méthodes de traitement les utilisant. L'invention concerne en outre des constructions d'anticorps anti-NKp80, des procédés de fabrication de celles-ci, et des méthodes de traitement les utilisant.
PCT/CN2025/122554 2024-09-20 2025-09-19 Protéines de liaison à nkp80 et leurs utilisations Pending WO2026061484A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2024/120119 2024-09-20
CN2024120119 2024-09-20

Publications (1)

Publication Number Publication Date
WO2026061484A1 true WO2026061484A1 (fr) 2026-03-26

Family

ID=99167345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/122554 Pending WO2026061484A1 (fr) 2024-09-20 2025-09-19 Protéines de liaison à nkp80 et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2026061484A1 (fr)

Similar Documents

Publication Publication Date Title
JP7843827B2 (ja) Ｂｃｍａを標的とするキメラ抗原受容体及びその使用方法
AU2019340333B2 (en) Single-domain antibodies against CLL1 and constructs thereof
JP2025159117A (ja) 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
US20240173352A1 (en) Cell-surface receptors responsive to loss of heterozygosity
KR20170128234A (ko) Ror1에 특이적인 항체 및 키메라 항원 수용체
JP7584453B2 (ja) Ｔａｃｉを標的とする抗体及びキメラ抗原受容体
TW201920657A (zh) 藉由細胞表現之調控生物活性的抗體
WO2023006118A1 (fr) Anticorps anti-cd33 et leurs utilisations
US20240180968A1 (en) Adgre2 chimeric receptor nk cell compositions and methods of use
WO2024046468A1 (fr) Protéines de fusion ciblant la voie de dégradation lysosomale
WO2023006117A1 (fr) Anticorps contre cll1 et leurs constructions
JP2024516748A (ja) ＥＧＦＲｖＩＩＩ結合タンパク質
JP2026507388A (ja) 新規ｃｄ１９標的化ポリペプチドおよびｃｄ１９標的免疫療法
WO2026061484A1 (fr) Protéines de liaison à nkp80 et leurs utilisations
JP2025529903A (ja) デルタ様リガンド３（ｄｌｌ３）に特異的な抗体およびキメラ抗原受容体
JP2025528177A (ja) Ｐｓｍａに向けられた親和性結合実体及びその使用方法
WO2026008059A1 (fr) Constructions anti-dll3 et leurs utilisations
WO2025201418A1 (fr) Cellules immunitaires modifiées et leurs utilisations
WO2026021525A1 (fr) Fractions de liaison à gprc5d et leurs utilisations
US20250339529A1 (en) B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof
WO2026077446A1 (fr) Constructions d'il-15 modifiées et leurs utilisations
WO2025016450A1 (fr) Combinaison d'une thérapie par antagoniste ciblant cldn18.2 et gucy2c
JP2026513651A (ja) Ａｄｇｒｅ２キメラ受容体ｎｋ細胞組成物及び使用方法
WO2024073111A2 (fr) Entités de liaison par affinité dirigées vers b7h6 et leurs procédés d'utilisation
WO2024111635A1 (fr) Anticorps contre le cancer hématologique